Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 16, 2025, titled "Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma".